Comparative randomised trial of high and conventional doses of praziquantel in the treatment of schistosomiasis mansoni
Queiroz, Leonardo C de; Drummond, Sandra C; Matos, Maria Laura M de; Paiva, Mariana BS; Batista, Thaís S; Kansaon, Ahraby ZM; Antunes, Carlos Maurício de F; Lambertucci, José Roberto.
Mem. Inst. Oswaldo Cruz
; 105(4): 445-448, July 2010. tab
Artículo
en Inglés
| LILACS | ID: lil-554810
The efficacy of oral praziquantel in the treatment of schistosomiasis has been considered low by most public health institutions. In this paper, we compared the efficacy of two dosages of praziquantel (80 mg/kg vs. 50 mg/kg) in patients with chronic schistosomiasis mansoni. Two hundred eighty-eight patients with schistosomiasis from a community in Brazil were randomly divided into two groups 145 patients (Group 1) received 80 mg/kg body weight of oral praziquantel divided in two equal doses with 1 h interval and 143 patients (Group 2) received 50 mg/kg body weight of oral praziquantel. To keep the study masked, patients in Group 2 received placebo 1 h after the first dose. All patients were subjected to clinical and ultrasonographic examination. Cure assessment was performed by repeating two stool examinations, by a quantitative method, at 30, 90 and 180 days after treatment. The morbidity of schistosomiasis was low, with a few cases of light periportal thickening and 16 cases of mild splenomegaly. The cure rates were 89.7 percent for Group 1 and 83.9 percent for Group 2. There was no difference in the efficacy of both therapeutic dosages of praziquantel assayed. The adverse reactions were more frequent with higher dosage.
Biblioteca responsable:
BR1.1
Texto completo